Adocia SA
PAR:ADOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adocia SA
Change in Working Capital
Adocia SA
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Adocia SA
PAR:ADOC
|
Change in Working Capital
-€7.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Valneva SE
PAR:VLA
|
Change in Working Capital
-€2.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Change in Working Capital
-€20.9m
|
CAGR 3-Years
28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-53%
|
|
|
Inventiva SA
PAR:IVA
|
Change in Working Capital
€4.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Change in Working Capital
$783k
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-18%
|
|
|
Abivax SA
PAR:ABVX
|
Change in Working Capital
€21.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Adocia SA
Glance View
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
See Also
What is Adocia SA's Change in Working Capital?
Change in Working Capital
-7.8m
EUR
Based on the financial report for Jun 30, 2025, Adocia SA's Change in Working Capital amounts to -7.8m EUR.
What is Adocia SA's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
5%
The average annual Change in Working Capital growth rates for Adocia SA have been -7% over the past three years , and 5% over the past ten years .
